Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
By Xiaodong Li, M. Ominsky, K. Warmington, S. Morony, Jianhua Gong, Jin Cao, Yongming Gao, V. Shalhoub, B. Tipton, R. Haldankar and 10 more. Journal of Bone and Mineral Research, 2009
773 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Orthopedics and Sports Medicine
View Paper: https://www.semanticscholar.org/paper/853f407a66096fd3eef2c52e4d91164f293e9619
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Molecular Biology
In Orthopedics and Sports Medicine
Citations in the corpus
- Osteoclast differentiation by RANKL and OPG signaling pathways (2020, background): “The administration of an anti-sclerostin-neutralizing antibody has been shown to increase bone mass with increased bone formation [34].”
- Romosozumab in postmenopausal women with low bone mineral density (2014, neutral): “Serious adverse event 7 (14) 4 (8) 5 (9) 5 (10) 17 (7)”
- Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody (2011, background): “Rats treated with a sclerostin antibody not only experience complete reversal of estrogen deficiency–induced bone loss atmultiple skeletal sites but also have further increases in bone mass and bone strength to levels greater than nonovariectomized controls.((20)) Sclerostin inhibition in monkeys in”
- Inflammatory bone loss: pathogenesis and therapeutic intervention (2012, background): “The primary end point was met with a statistically significant increase in lumbar spine BMD at 12 months in the active arm compared with the placebo arm, and the antibody was reported to have compared positively with the two active comparators, teriparatide and alendronat”